CLNN

$CLNN chatter on StockTwits

• 
  Bob Avery@Ravery8m

  $CLNN The issue right now is financial uncertainty. The market punishes balance sheet uncertainty plain and simple. I hope they opt to provide transparency on the upcoming q2 call. The stock could potentially recover on a sizable dilutive event. If they leave it as 'we are going to need to go to the market to raise more funds', keeps a dark cloud over the shares. The science will continue to take a back seat until this is addressed. The longer the dark cloud remains, the lower the price could go, the more dilutive a placement could be. Transparency would be my advice for this management team FWIW.

  View on StockTwits ↗
• 
  Chris@Chris150Bullish10m

  $CLNN Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights https://invest.clene.com/news-releases/news-release-details/clene-reports-second-quarter-2026-financial-results-and-recent

  View on StockTwits ↗
• 
  Kay WashingtonD@Cresskill1981h

  $CLNN I think a lot of people are misunderstanding the financing issue around CLNN. Yes, FDA has told Clene that the confirmatory Phase 3 trial needs to be underway before an accelerated-approval decision. But that does NOT mean CLNN needs tens of millions of dollars upfront to fully fund an 800-patient Phase 3 before approval. The company only needs sufficient capital to initiate the trial and get enrollment underway. The much larger funding requirement comes later as the trial progresses. To get a trial “underway,” Clene would need to spend money on things such as: * CRO/site contracts * regulatory and site activation * investigator payments * manufacturing/clinical drug supply * patient recruitment * screening * initial patient dosing * trial management and monitoring It doesn’t mean enrolling hundreds of patients before the FDA decision. To cover the above cost $5–10M is a reasonable range. - continued-

  View on StockTwits ↗
• 
  Cary T@Spectaculator14h

  $CLNN CEO needs to take public speaking classes, and CFO needs to take classes on how to look professional and awake.

  View on StockTwits ↗
• 
  leasha@k_rma15h

  $CLNN I found the majority of this useful https://chatgpt.com/share/6a7e3256-99b8-83ea-bb9a-af10ef3aebf2

  View on StockTwits ↗
• 
  Bob freemam@BobfreeBullish17h

  $CLNN added for first time in 6 months or so. Might have to sell some things to free cash to buy more tomorrow.

  View on StockTwits ↗
• 
  Kay WashingtonD@Cresskill19821h

  $CLNN That’s not quite how I understand the accelerated-approval pathway. The Phase 3 confirmatory trial is a post-approval requirement—it does not mean CLNN has to complete a massive Phase 3 trial before FDA can grant AA. FDA generally wants the confirmatory trial underway around the time of approval, and CLNN has already said RESTORE-ALS is intended to be that post-approval confirmatory study, with initiation planned for Q1 2027. More importantly, CLNN has already structured financing around the regulatory milestones: the January financing included additional tranches tied specifically to NDA acceptance and FDA approval, expected to provide capital into early 2027. If the NDA is accepted and AA is granted, CLNN can commercialize CNM-Au8 and start generating revenue. The financing problem before approval and the financing picture after approval are two very different things.

  View on StockTwits ↗
• 
  Kay WashingtonD@Cresskill19821h

  $CLNN The missing piece here is the timeline. CLNN doesn’t need to finance itself indefinitely before approval. The goal is to bridge the relatively short period to NDA acceptance and an FDA decision, with approval potentially in 1H 2027. Once the NDA is accepted, that’s a major de-risking event. If CNM-Au8 gets approved, CLNN can sell the drug and generate revenue while the phase 3 can start. Funding suddenly becomes a very different problem. Yes, dilution is a risk—but assuming CLNN has to raise a massive amount of money at $3–$3.50 ignores the fact that the company only needs to bridge to a potentially transformational catalyst. That’s exactly why I’m not selling based on short-term financing anxiety. But, I advise you sell. This stock will start turning around after all these people are gone.

  View on StockTwits ↗
• 
  unknown user@Acx21Bullish21h

  $CLNN guys, I get your point: You are afraid CLNN is running out of money into bankruptcy or insane dilution. But being a controller myself I can assure you, the people in CLNN's finance department know their business. The know their costs, the know their cash amount, they know when they run out of cash. And still, they knew how to convince in january three major biotech investor companies (boxer, vivo, coastlands) and in may a single investor to buy share/warrants as well as to change the debt amendment in a very favorable way. Do you really think these investors wouldnt request insights into liquidity and into a financial plan? You can always tell the best salesmen stories about a product but numbers are numbers. You can make them better using fancy words. And despite the cash situation already being not perfect a couple of months (3 (may) or 7 (january)) these investors invested nevertheless... So calm down 😉

  View on StockTwits ↗
• 
  Ryan Mulholland@MulhollandrBullish23h

  $CLNN getting the word out. 👍🏻

  View on StockTwits ↗
• 
  Ryan Mulholland@MulhollandrBullish23h

  $CLNN

  View on StockTwits ↗
• 
  Ryan Mulholland@MulhollandrBullish23h

  $CLNN https://alsnewstoday.com/news/nfl-changes-may-help-predict-benefit-treatment-als/

  View on StockTwits ↗
• 
  Paul@paule8151d

  $CLNN Please, stay optimistic here. I’ve never told you outlandish expectations. The lights are on and people are working.

  View on StockTwits ↗
• 
  Richard Albanese@pyracon1d

  $CLNN One obvious reason for this stocks pitiful performance is the company's inability to meet a single announced date of importance. If you say you're going to release quarterly results on the 12th then don't look unreliable and incompetent by not releasing those quarterly results on the 12th. When have they once met their own announced date, of what I would call an obligation to their shareholders? Why even put it out there if you are going to 100% not do it and look more irresponsible then you've already been? Whenever this company puts out in writing that something will happen on a particular date you can 1,000% know beyond all doubt they will miss that date. As we're seeing with filing the NDA. That miss is now measured in months or possibly more than a year. They operate more like inexperienced adolescents than seasoned executives. It' no wonder they rarely, if ever, face their shareholders. every

  View on StockTwits ↗
• 
  Steve@Woodman71d

  $CLNN - with over 22,000 shares, I’m looking at this as probably a 50/50 bet. Either I lose $100K or I make $500K - $1M over the next few years. I believe this is a good bet rn. (Also, given their patents and progress on multiple fronts, I don’t ever see this going to zero - all in, there is plenty of latent value. ) I just think that most investors are unwilling to take the risk associated with this binary outcome as it gets closer to decision time /reality. Nail-biting time…

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.